Key result
Cardiac progenitor/stem cells yielded greater improvement in cardiac function and smaller infarct size after myocardial infarction in rats compared with bone marrow mesenchymal stem cells.
Why the study?
Lower doses of CPCs improve cardiac function compared to BM-MSCs after MI, but the surface protein expression profile explaining this effect remained to be investigated.
Does transplantation of human cardiac progenitor/stem cells improve cardiac function and reduce infarct size compared to bone marrow mesenchymal stem cells in a rat model of myocardial infarction?
Does transplantation of human cardiac progenitor/stem cells improve cardiac function and reduce infarct size compared to bone marrow mesenchymal stem cells in a rat model of myocardial infarction?
Human cardiac progenitor cells demonstrate superior engraftment and functional improvement compared to bone marrow mesenchymal stem cells in a rat MI model, likely due to enhanced cell adhesion expression.
Cautions against clinical stem cell dosing changes in MI; leaves open CPC efficiency mechanisms for human trials.
Human bone marrow mesenchymal stem cells (BM-MSCs) and cardiac progenitor/stem cells (CPCs) have been extensively studied as a potential therapeutic treatment for myocardial infarction (MI). Previous reports suggest that lower doses of CPCs are needed to improve cardiac function relative to their bone marrow counterparts. Here, we confirmed this observations and investigated the surface protein expression profile that might explain this effect. Myocardial infarction was performed in nude rats by permanent ligation of the left coronary artery. Cardiac function and infarct size before and after cell transplantation were evaluated by echocardiography and morphometry, respectively. The CPC and BM-MSC receptome were analyzed by proteomic analysis of biotin-labeled surface proteins. Rats transplanted with CPCs showed a greater improvement in cardiac function after MI than those transplanted with BM-MSCs, and this was associated with a smaller infarct size. Analysis of the receptome of CPCs and BM-MSCs showed that gene ontology biological processes and KEGG pathways associated with adhesion mechanisms were upregulated in CPCs compared with BM-MSCs. Moreover, the membrane protein interactome in CPCs showed a strong relationship with biological processes related to cell adhesion whereas the BM-MSCs interactome was more related to immune regulation processes. We conclude that the stronger capacity of CPCs over BM-MSCs to engraft in the infarcted area is likely linked to a more pronounced cell adhesion expression program.
No takes yet. Share an insight, caveat, or question.
Ontoria‐Oviedo et al. (2020) studied Myocardial infarction. Cardiac progenitor/stem cells (CPCs) vs. Bone marrow mesenchymal stem cells (BM-MSCs) was evaluated on Cardiac function and infarct size. Cardiac progenitor/stem cells yielded greater improvement in cardiac function and smaller infarct size after myocardial infarction in rats compared with bone marrow mesenchymal stem cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: